Korean biotech Bertis to join BIO 2024 for global reach

South Korean biotech Bertis Inc. will deliver presentations at the BIO International Convention, one of the world’s largest bio and healthcare industry conferences, to introduce its proteomics-based cancer diagnosis technologies and expand global networks

The company said on Tuesday it will introduce its technology of early cancer detection and commercialized testers and will seek business partnerships with overseas biotechs and drugmakers during the event held at the San Diego Convention Center from June 3 to 6.

It will give a company introduction at the Seoul Bio Forum on June 3, an investor relations session for Korean biotech firms seeking expansion in the US. Bertis will present its early disease detection technology and business growth strategy to venture capital managers, biopharmaceutical companies and law firms at the session.

On June 5, Bertis will deliver an in-depth presentation on its proteomics-based blood tester pipelines and omics-based clinical analysis, named Pan-omics Analysis Service & Solution (PASS), for potential partnerships with global companies.

“Proteomics is essential for precision medicine and will play a critical role in addressing key challenges faced by the global medical and healthcare industries. We will share Bertis’ in-house technology and business and explore partnership opportunities to accelerate the introduction of proteomics-based technology and products,” said Bertis Chief Executive Han Seung-man.

Founded in 2014, Bertis specializes in proteomics technology ranging from protein data analysis to commercialization of related services and products. It posted more than 170,000 cumulative diagnoses last year. 

The company launched Mastocheck, a blood tester for proteomics-based early breast cancer detection, in Korea and Singapore in 2019. Early pancreatic and ovarian cancer diagnosis technologies are under development.  

The biotech attracted 20 billion won ($14.6 million) in its pre-initial public offering funding in February. Among the investors are state-run Korea Development Bank and local VC firms including Winvest Venture Partners, Premier Partners and BNH Investment.

Write to Woo-Sang Lee at idol@hankyung.com

Jihyun Kim edited this article.